Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and …
T Jojima, K Uchida, K Akimoto, T Tomotsune, K Yanagi… - Atherosclerosis, 2017 - Elsevier
Background and aims Several studies have demonstrated that both native glucagon-like
peptide-1 (GLP-1) and GLP-1 receptor agonists suppress the progression of atherosclerosis
in animal models. Methods We investigated whether liraglutide, a GLP-1 analogue, could
prevent the development of atherosclerosis in apolipoprotein E knockout mice (ApoE−/−) on
a high-fat diet. We also examined the influence of liraglutide on angiotensin II-induced
proliferation of rat vascular smooth muscle cells (VSMCs) via enhancement of AMP …
peptide-1 (GLP-1) and GLP-1 receptor agonists suppress the progression of atherosclerosis
in animal models. Methods We investigated whether liraglutide, a GLP-1 analogue, could
prevent the development of atherosclerosis in apolipoprotein E knockout mice (ApoE−/−) on
a high-fat diet. We also examined the influence of liraglutide on angiotensin II-induced
proliferation of rat vascular smooth muscle cells (VSMCs) via enhancement of AMP …